Temozolomide-induced inflammation of disseminated superficial actinic porokeratosis

Dylan E Lee; Benjamin H Kaffenberger; Alejandro A Gru; Dathan Hamann

Temozolomide-induced inflammation of disseminated superficial actinic porokeratosis

Dermatol Online J. 2018 Mar 15;24(3):13030/qt25m6s6nc.

Authors

Dylan E Lee, Benjamin H Kaffenberger, Alejandro A Gru, Dathan Hamann¹

Affiliation

¹ Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Gahanna, Ohio. [email protected].

PMID: 29634886

Abstract

We report a case of temozolomide (TMZ)-induced inflammation of disseminated superficial actinic porokeratosis (DSAP), an uncommon and pre-malignant cutaneous disorder. Dermatologists and oncologists should be aware of this cutaneous eruption of DSAP associated with TMZ to prevent the discontinuation of effective medical therapy in cancer patients.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Agents, Alkylating / therapeutic use
Biopsy
Dacarbazine / adverse effects
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Humans
Inflammation / chemically induced*
Inflammation / pathology
Male
Middle Aged
Porokeratosis / chemically induced*
Porokeratosis / pathology
Skin / drug effects
Skin / pathology*
Temozolomide

Substances

Antineoplastic Agents, Alkylating
Dacarbazine
Temozolomide